These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23319451)

  • 1. Low rate of bone density testing in men receiving androgen deprivation therapy.
    Barton MK
    CA Cancer J Clin; 2013; 63(2):85-6. PubMed ID: 23319451
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.
    Cheung AS; Pattison D; Bretherton I; Hoermann R; Lim Joon D; Ho E; Jenkins T; Hamilton EJ; Bate K; Chan I; Zajac JD; Grossmann M
    Andrology; 2013 Jul; 1(4):583-9. PubMed ID: 23686896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for osteoporosis in men receiving androgen deprivation therapy.
    Alibhai SM; Yun L; Cheung AM; Paszat L
    JAMA; 2012 Jan; 307(3):255-6. PubMed ID: 22253389
    [No Abstract]   [Full Text] [Related]  

  • 6. [Osteoporosis due to androgen suppression therapy in men with prostate cancer].
    Roux C
    Prog Urol; 2003 Apr; 13(2 Suppl 1):24-7. PubMed ID: 12815806
    [No Abstract]   [Full Text] [Related]  

  • 7. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of osteoporosis in men on androgen deprivation therapy.
    Adler RA
    Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer treated with androgen deprivation therapy has consequences for bone.
    Adler RA
    Endocrine; 2014 Apr; 45(3):339-40. PubMed ID: 24366636
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone health care for patients with prostate cancer receiving androgen deprivation therapy.
    Tsang DS; Alibhai SM
    Hosp Pract (1995); 2014 Apr; 42(2):89-102. PubMed ID: 24769788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 14. Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.
    Bruder JM
    Curr Urol Rep; 2005 May; 6(3):157-8. PubMed ID: 15869718
    [No Abstract]   [Full Text] [Related]  

  • 15. Bisphosphonate prescriptions in men with androgen deprivation therapy use.
    Gulamhusein H; Yun L; Cheung AM; Sutradhar R; Paszat L; Warde P; Alibhai SM
    JAMA; 2014 Dec; 312(21):2285-6. PubMed ID: 25462000
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone loss in men under androgen-deprivation therapy for prostate cancer].
    Ishizaka K; Machida T; Yoshida K
    Nihon Rinsho; 2005 Apr; 63(4):721-6. PubMed ID: 15828242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study.
    Nadler M; Alibhai S; Catton P; Catton C; Jones J
    Support Care Cancer; 2014 Sep; 22(9):2409-15. PubMed ID: 24696083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.